Dendreon Corp fka DNDNQ

[bobrmd]

I have a problem with the 483 and dendreon management as do you. I agree cege has an active pipeline and are more actively pursuing immunomodulatory drgs in ombination with gvax.

I dont beieve that vital one passed any interim look or should I say were allowed to continue the trial based on strict rigid statistical criteria. I dont know who the well respected observers who felt vital one would be stopped. The only opinions I've seen seemed to be that vital 1 would be allowed to continue after an unsuccesful interim. Not because of passing some strict statistical criteria, but rather because the trial was fully enrolled and posed no major toxicities. There are examples of drugs that were actually stat inferior that later showed a benefit. So lacking any toxicity the data collection continues. I doubt whether cege knows the stat reslts of the interim. Even if they did it would be a pr nightmare to stop the trial at the interim if the data looked really unfavorable. It doesnt cost much to contine to follow the patients.

As an aside, Most people feel vital 2 has a better chance for success.It is also in the companies interest to keep vital one going to allow the final results to come out close to the timing of the results of vital 2. If vital one fails, then damage could be minimzed by hyping the fact that vital 2 results are coming soon and have a greater chance for success IMHO.